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SUMMARY 
Pulmonary arterial hypertension (PAH) is a progressive disease defined by an 
elevation of pulmonary vascular resistance due to sustained vessel contraction 
and enhanced vascular remodeling. The abnormal tone and remodeling in the 
pulmonary vasculature are believed to be related, at least in part, to the 
decrease of cyclic nucleotide levels that are controlled by cyclic nucleotide 
phosphodiesterases (PDEs).  
 
PDEs, of which 11 families have been identified, maintain homeostasis of the 
second messengers by catalyzing the hydrolysis of cAMP and cGMP with 
diverse compartmentalization and substrate specificities. Interestingly, 
increased expression of some PDE isoforms has been observed in PAH and 
beneficial effects of PDE5 inhibitors, PDE1 inhibitors and PDE3/4 inhibitors 
have been reported in clinical or experimental PAH. The role of PDE7-11 in 
PAH has not been investigated, thus we aimed to investigate the expression 
profile of those higher isoforms. In addition, we were interested in the 
contribution of these enzymes to the pathophysiology of PAH using the well-
established monocrotaline (MCT)-induced pulmonary hypertensive rat model.  
 
In this study, a prominent increase of PDE10A expression was observed 
among the multiple newly identified PDEs (PDE7-11) which are all present in 
lung tissue. Interestingly, the upregulation of PDE10A is specific in the 
pulmonary vasculature of pulmonary hypertensive subjects without significant 
changes in the systemic vasculature such as aorta or femoral artery.  
 
As one of the most recently described PDEs, PDE10A is characterized as a 
cAMP-PDE and a cAMP-inhibited cGMP-PDE. Research on PDE10 is mainly 
focused on neurological studies because of its abundant expression in the brain. 
We demonstrated for the first time the predominant localization of PDE10A in 
the media of the small pulmonary arteries and nuclear compartmentalization in 
pulmonary arterial smooth muscle cells (PASMCs). In accordance, both 
PDE10A expression and cAMP hydrolyzing activity are remarkably increased in 
PASMCs from MCT-induced PH rats as compared to control rats, suggesting a 
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contribution of PDE10A to the proliferative phenotype of PASMCs in the 
process of PH. Futher more, PDE10A immunoreactivity is strongly increased in 
pulmonary arteries of IPAH patient lung sections as compared to the donors, 
indicating clinical relevance of the findings obtained from the MCT model. 
 
The anti-proliferative effect of PDE10 inhibition is proved to be largely relevant 
to an increase of intracellular cAMP levels that may subsequently alter 
downstream signaling events such as phosphorylation of the cAMP response 
element binding protein (CREB). In our investigation, we found that inhibition of 
PDE10A by employing a selective inhibitor of PDE10 (papaverine) or PDE10A 
specific small interfering RNA (siRNA) promoted intracellular cAMP generation, 
induced CREB phosphorylation and attenuated proliferation of PASMCs from 
MCT-induced PH rats.  
 
Furthermore, treating MCT-PH rats with the PDE10 inhibitor papaverine for 14 
days by intravenous infusion markedly reduced right ventricular systolic 
pressure values as well as total pulmonary vascular resistance index, without 
effects on the systemic arterial pressure. In addition, the percentage of fully 
muscularized peripheral pulmonary arteries was significantly decreased.  
 
Taken together, this study supports a central role of PDE10A in progressive 
pulmonary vascular remodeling and suggests a novel therapeutic opportunity 
for the treatment of pulmonary arterial hypertension. 
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ZUSAMMENFASSUNG 
Die pulmonal-arterielle Hypertonie (PAH) ist durch einen zunehmend 
ansteigenden Gefäßwiderstand definiert, welcher durch dauerhafte Kontraktion 
kleiner Pulmonalarterien und ein verstärktes vaskuläres Remodeling zu einem 
Anstieg des Blutdrucks im Lungenkreislauf führt. Diese pathologischen 
Veränderungen der Pulmonalgefäße werden u.a. auf ein geringeres 
Vorhandensein der zyklischen Nukleotide cAMP und cGMP zurück geführt, was 
maßgeblich durch die Aktivität zyklischer Nukleotid- Phosphodiesterasen 
(PDEs) bestimmt wird. 
 
Die Familie der PDEs umfasst derzeit 11 Mitglieder. Sie hydrolysieren cAMP 
und cGMP zu AMP bzw. GMP und haben durch ihre zelluläre und intrazelluläre 
Verteilung und Substratspezifität einen bedeutenden Einfluss auf die 
Homöostase dieser second messenger. Sowohl in experimenteller PAH als 
auch in klinischen PAH-Studien konnte bereits gezeigt werden, dass eine 
erhöhte Expression bestimmter PDEs vorliegt und dass die Behandlung mit 
PDE5-, PDE1- und PDE3/4-Inhibitoren gefäßerweiternd wirkt und zudem einen 
antiproliferativen und antimigrativen Effekt auf vaskuläre Zellen hat. Die Rolle 
der PDEs 7 bis 11 in PAH ist bisher jedoch noch unzureichend erforscht. Daher 
war unser Ziel heraus zu finden, ob Mitglieder dieser PDEs in der 
Pathophysiologie der PAH eine Rolle spielen. Für diese Untersuchungen diente 
uns das bereits etablierte experimentelle Modell der Monocrotalin (MCT) -
induzierten pulmonalen Hypertonie in der Ratte.  
 
Bei der Untersuchung der PDE-Expression im Lungengewebe zeigte sich 
neben der Expression der PDEs 7 bis 9 und der PDE11 eine deutlich erhöhte 
Expression der PDE10A. Diese konnte zudem spezifisch in der verdickten und 
veränderten Gefäßmuskulatur der Pulmonalarterien immunhistochemisch 
lokalisiert werden. In systemischen Gefäßen wie der Aorta oder der 
Femoralarterie konnten jedoch keine signifikanten Veränderungen in der 
PDE10A-Expression festgestellt werden.  
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Als eine der erst kürzlich beschriebenen PDEs wird die PDE10A als cAMP-
PDE und als cAMP-inhibierte cGMP-PDE bezeichnet und wird wegen ihres 
Vorkommens im Gehirn hauptsächlich in neurologischen Studien untersucht. In 
dieser Arbeit konnten wir erstmalig zeigen, dass die PDE10A eine 
vorherrschende Expression in der Media kleiner Pulmonalarterien aufweist und 
in pulmonal-arteriellen glatten Muskelzellen (PASMCs) überwiegend nukleär 
lokalisiert ist. Im Vergleich zu Kontroll-PASMCs ist sowohl die Expression als 
auch die cAMP-hydrolysierende Aktivität der PDE10A in PASMCs aus MCT-
injizierten Ratten deutlich erhöht, was eine Mitwirkung der PDE10A bei der 
Proliferation der PASMCs und dem Fortschreiten der PAH vermuten lässt. 
Desweiteren ist die PDE10A Immunoreaktivität in pulmonalen Arterien der 
untersuchten Lungenbereiche von IPAH Patienten im Vergleich zu denen der 
Spender stark erhöht, was darauf hinweist, daß eine klinische Relevanz dieser 
Ergebnisse, die vom MCT Modell gezeigt wurden vorliegt. 
 
Phosphodiesterase-Inhibitoren führen meist zu einer Erhöhung der 
intrazellulären cAMP-Konzentration, was im Folgenden Auswirkungen auf den 
Phosphorylierungsstatus und somit die Aktivität von Transkriptionsfaktoren wie 
CREB (cAMP response element binding protein) hat. Unsere Untersuchungen 
zeigten, dass die Hemmung der PDE10A durch Verabreichen des Inhibitors 
Papaverin oder durch die Verwendung PDE10A-spezifischer kleiner 
einzelsträngiger RNAs (siRNAs) zu einer gesteigerten intrazellulären cAMP-
Konzentration führt, die Phosphorylierung von CREB induziert und die 
Proliferation von PASMCs aus MCT-injizierten Ratten mit PAH vermindert. 
Überdies wird die PASMC-Proliferation, verglichen mit der Hemmung weiterer 
cAMP-abbauender PDEs, am meisten durch Inhibition der PDE10A verringert. 
 
Die Behandlung von MCT-PH-Ratten mit dem PDE10A Inhibitor Papaverin für 
14 Tage per intravenöse infusion reduzierte deutlich den systolischen Druck 
des rechten Ventrikels ebenso wie den gesamten pulmonal-vaskulären 
Widerstand, ohne den systemische Blutdruck zu beeinflussen. Ebenso war der 
Prozentsatz von voll muskularisierten peripheren pulmonalen Arterien deutlich 
durch diesen therapeutischen Ansatz gehemmt. 
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 Zusammenfassend deuten diese Ergebnisse darauf hin, dass die PDE10A 
eine zentrale Rolle im vaskulären Remodeling-Prozess einnimmt und daher ein 
therapeutisches Ziel zur Behandlung von pulmonaler Hypertonie darstellen 
könnte.
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1 INTRODUCTION 
1.1 Pulmonary hypertension (PH) 
Pulmonary hypertension is a fatal disease which is clinically characterized by a 
progressive rise in pulmonary vascular pressure. When untreated, right 
ventricle overload leads to right ventricular hypertrophy and in the end stage 
right heart failure and death with an average survival time as short as 2.8 
years1. Pulmonary hypertension has a multifactorial pathobiology. Moreover, 
available therapies for PH were shown to improve the prognosis, but not to cure 
the disease. 
 
1.1.1 Definition of pulmonary hypertension 
The first description came from autopsy specimens more than a century ago by 
a German physician- Ernst von Romberg2, and until 1951 the first clinical and 
hemodynamic study was made ante mortem3. In pulmonary hypertension the 
average pressure in the pulmonary artery is higher than 25 mmHg at rest or 30 
mmHg during physical activity, while the pressure in a normal pulmonary artery 
is about 15 mmHg at rest4.  
 
1.1.2 Classification of pulmonary hypertension 
Pulmonary hypertension was initially classified into two categories including 
primary pulmonary hypertension and secondary pulmonary hypertension5, 
simply based on the presence or absence of identifiable causes. With more 
understanding of the disease, the classification of PH has gone through a 
series of changes. The latest and probably the best classification up to now is 
the Dana Point Classification made on the 4th World Symposium on PH held in 
2008 in Dana Point, California,  which divided the PH into five groups6 (Figure 1) 
that shared similar pathophysiologic mechanisms and clinical presentation as 
well as therapeutic approaches. 
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Tabel 1: Updated classification of PH (Dana Point, 2008) 
 
1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic PAH 
1.2. Heritable 
1.2.1. BMPR2 
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
1.2.3. Unknown 
1.3. Drug- and toxin-induced 
1.4. Associated with 
1.4.1. Connective tissue diseases 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
1.4.6. Chronic hemolytic anemia 
1.5 Persistent pulmonary hypertension of the newborn 
1’. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH) 
              
2. Pulmonary hypertension owing to left heart disease 
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell 
histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on 
dialysis 
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1.1.3 Histology and concepts of pulmonary arterial hypertension (PAH) 
pathology 
1.1.3.1 Histology and pathology 
The common histological features in PAH are the remodeling of all three layers 
of the pulmonary vasculature (intimal, medial and adventitia layer) as well as 
the formation of plexiform lesion (Figure 1)4.  
 
A)                     B) 
 
 
 
 
 
 
 
Figure 1: Histology of PAH. A) Muscular pulmonary artery from a PAH patient with 
medial hypertrophy (white arrow), luminal narrowing by intimal proliferation (black arrow), 
and proliferation of adventitia (X). B) Characteristic plexiform lesion from an obstructed 
muscular pulmonary artery (black arrow). (Gaine, S. P. & Rubin L. J., 1998)4 
 
The abnormalities of the pulmonary vasculature comprise 1) medial 
hypertrophy of large pulmonary arteries and muscularization of distal 
precapillary arteries; 2) proliferation in the adventitia of small pulmonary arteries 
and arterioles; 3) intimal hyperplasia that is particularly occlusive in vessels at 
100–500 µM; 4) plexiform lesions of arterial branches distal to an obstructed 
larger artery; 5) loss of precapillary arteries7, 8 (Figure 2). 
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Figure 2: Scheme of pathological abnormalities in PH throughout the pulmonary 
circulation. (Rabinovitch,M.,2008)7 
 
 
1.1.3.2 Molecular and cellular regulators 
Diverse stimuli like inflammation, shear stress and hypoxia lead to 1) 
vasoconstriction, due to the imbalance between vasodilators and 
vasoconstrictors; 2) vascular remodeling, resulting from the imbalance between 
mitogenic and anti-mitogenic mediators; 3) in situ thrombosis caused by 
abnormalities of blood coagulation factors and fibrinolytic factors9, 10, all of 
which result in increased pulmonary pressure in PAH. Recent pathophysiologic 
studies have addressed evidences on a couple of key factors mediating the 
process of PAH, among which nitric oxide, prostacyclin, vasoactive intestinal 
peptide, Endothelin-1, potassium channels and serotonin11-13 are widely 
investigated. 
 
1.3.3.2.1 Nitric oxide 
Over the past decades, nitric oxide (NO), which is synthesized by a family of 
NO synthase enzyme (NOS) from the amino acid L-arginine in endothelial cells, 
is believed to be a vasodilator targeting SMC on soluble guanylyl cyclase 
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(sGC)/vasorelaxation pathway. The activation of sGC in SMCs leads to cGMP 
accumulation and consequently PKG activation and reduction of intracellular 
calcium, which leads to vasodilation. Cyclic GMP is removed by 
phosphodiesterases (PDEs). Diminished eNOS expression in pulmonary 
vasculature has been demonstrated in PH patients, particularly in IPAH 
patients14. Furthermore, eNOS-null mice are more susceptible to stimuli that 
trigger pulmonary hypertension as compared to the wild-type mice15, 16, 
suggesting that NO not only acts as a vasodilator, but also inhibits smooth 
muscle cell proliferation17 and platelet aggregation18. All of these factors 
indicates that NO plays an important role in PAH. 
 
1.3.3.2.2 Prostacyclin and thromboxane A2  
Prostacyclin is an arachidonic acid metabolites, and is synthesized in 
endothelial cells by prostacyclin synthase. It is a vasodilator and can prevent 
vascular SMC proliferation and platelet aggregation via adenylate cyclase 
(AC)/cAMP-dependent pathways. Thromboxane A2 is produced by endothelial 
cells and platelets and increases vasoconstriction and activates platelets19. In 
patients with PAH, decreased level of prostacyclin accompanied by increased 
level of thromboxane A2 were observed by urine analysis20. Correspondingly, 
expression of prostacyclin synthase is reduced in small and medium-sized 
pulmonary arteries in PAH patients21. Therefore the imbalance between 
prostacyclin and thromboxane A2 favours vasoconstriction, thrombosis, as well 
as vessel wall remodeling associated with PAH development.  
 
1.3.3.2.3 Vasoactive intestinal peptide (VIP) 
Decreased VIP immunoreactivity in serum and lung tissue, shown in  IPAH 
patients, may contribute to the pathogenesis of PAH considering its potential 
roles as a pulmonary vasodilator and an inhibitor of PASMC proliferation and 
platelet aggregation22. VIP−/− mice exhibit spontaneous PAH in the absence of 
hypoxia and VIP may act as an endogenous modulator of calcineurin-NFAT 
(nuclear factor of activated T cells) transcriptional activation23, 24. It is also 
demonstrated that VIP may act through its receptors in vasculature to activate 
cAMP and cGMP systems22, but the key mechanisms involved are unclear. 
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1.3.3.2.4 Endothelin-1 (ET-1) 
ET-1 is predominantly produced by endothelial cells and is a potent 
vasoconstrictor. In addition, it acts as mitogen that promotes inflammation and 
SMC proliferation. Elevated ET-1 levels in lung and circulation are reported 
from rats with hypoxia-induced PAH25 and from PAH patients26, which strongly 
supports the concept that the endothelin system plays a crucial role in the 
development of PAH. The effects of ET-1 in the lung are complex and depend 
on two different ET-1 receptors named ETA and ETB. ETA presents mainly in 
SMCs while ETB locates in both SMCs and endothelia cells27. Through its 
action on ETA and  ETB in PASMCs, ET-1 evokes Ca2+ sparks in PASMCs via 
activation of phospholipase C and consequently causes vasoconstriction and 
sustained activation of protein kinase C, which mediates mitogenic actions28, 29. 
In contrast to the activation of ETB in PASMCs, ET-1 activates the endothelial 
ETB receptor, which leads to the release of vasodilator and antiproliferative 
agents  like NO and prostacyclin30 and promotes clearance of circulating ET-131 
in pulmonary vasculature. 
 
1.3.3.2.5 Potassium channels 
Reduced expression and function of voltage-gated potassium channels (Kv), 
notably Kv1.5 and Kv2.1, was observed in PASMCs either from IPAH patients32 
or from rats with hypoxia-induced PAH33. The selective loss of these Kv 
channels on PASMCs leads to membrane depolarization, sustained increase of 
the intracellular calcium by  Ca2+ influx,  and promotes both vasoconstriction 
and cell proliferation.  
 
1.3.3.2.6 Serotonin 
Serotonin (5-HT, 5-hydroxytryptamine) is considered as both a 
vasoconstrictor34 and a mitogen that promotes smooth muscle cell 
hypertrophy35. Elevated 5-HT in plasma was observed in IPAH patients. More 
recently, a number of studies showed that the 5-HT transporter (5-HTT) and 5-
HT receptors in the pulmonary vasculature are increased in both clinical and 
experimental PAH36, 37. In mice, selective 5-HTT inhibitors protect against 
hypoxic pulmonary hypertension38; while transgenic 5-HTT overexpression in 
smooth muscle results in PH39.  
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1.1.4 Pharmacological and clinical therapies 
Major pharmacological therapies include therapy with vasodilators and more 
recently therapy with agents targeting pulmonary vascular remodeling. To 
maximize therapeutic benefits and minimize side effects, combination therapy 
with existing drugs under different mechanisms of action is essential.  
 
1.1.4.1 Prostacyclin 
Prostacyclin analogues promote vasodilation as well as inhibit vascular 
proliferation and platelet aggregation40. Intravenous epoprostenol was the first 
approved approach to improve the symptoms and survival of PAH patients41, 42. 
Because of the short half-life of epoprostenol, longer-active prostacyclin 
alternatives such as iloprost and treprostinil with the same or better efficacy and 
less side effects have been developed in clinical trial for intravenous, 
subcutaneous or inhaled treatment of PAH43-46. 
 
1.1.4.2 Inhaled NO and sGC stimulators 
Inhaled NO, being delivered directly to pulmonary resistance vessels, has been 
proven to be a potent and selective pulmonary vasodilator with minor systemic 
effects47 via NO-sGC-cGMP pathway. Since long-term use of Inhaled NO is 
limited by its short half-life, drugs that activate sGC in a NO-independent 
manner are considered as innovative alternatives to direct NO donors48. 
Recently several compounds have shown beneficial effects on vasodilation and 
vessel remodeling via inhalation in experimental PAH animals49, 50. Moreover, 
riociguat (BAY 63-2521), a sGC stimulator, was reported to improve pulmonary 
hemodynamic parameters and cardiac index to a greater extend than inhaled 
NO in PAH patients51.  
 
1.1.4.3 Endothelin antagonists  
ET-1 acts as an important vasoconstrictor and mitogen in the development of 
PAH. Pharmacologic antagonists against ET-1 receptors with variable 
specificities are under a widespread investigation for PAH treatment. Oral 
bosentan, a dual endothelin receptor antagonist, improves hemodynamics and 
exercise capacity, as well as survival of PAH patients52, 53. However bosentan 
has been reported to cause liver dysfunction in a great percentage of patients. 
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While ETA specific antagonists consisting of sitaxsentan54 and ambrisentan55 
both improve exercise capacity of PAH patients in clinical trails, with a low 
incidence of hepatic toxicity.  
 
1.1.4.4 Phosphodiesterase 5 (PDE5) inhibitors 
Sildenafil was initially used for erectile dysfunction and subsequently proved to 
be a therapeutic candidate for PAH based on the high abundant expression of 
PDE5 in pulmonary vasculature as compared to systemic vasculature56, 57. By 
inhibiting the breakdown of cGMP, sildenafil can augment the NO-sGC-cGMP 
signaling in pulmonary vasculature, resulting in pulmonary vasodilation and 
inhibition of SMC proliferation. Beneficial effects including improved symptoms, 
hemodynamics, exercise capacity and survival have been shown by a one-year 
extension study after a daily oral treatment with sildenafil for 12 weeks57.  
 
1.1.4.5 Tyrosine kinase inhibitors 
Platelet-derived growth factor (PDGF), as a growth factor, induces cell 
proliferation and migration. In an experimental PH model, PDGF and its 
receptors are increased and by applying imatinib, a multi-inhibitor for tyrosine 
kinase, the pulmonary vascular remodeling process was reversed58.  
Furthermore, beneficial effects of imatinib on PAH patients have also been 
shown in three cases of clinical trails59-61. But more evaluations with much 
larger number of PAH patients are required in randomized clinic studies. 
 
1.2 Phosphodiesterases (PDEs) 
1.2.1 Cyclic nucleotides (cAMP and cGMP) 
Adenosine 3’, 5-cyclic monophosphate (cAMP) and guanosine 3’, 5’-cyclic 
monophosphate (cGMP) have been defined as second messengers half a 
century ago62. Both cAMP and cGMP play critical roles in various tissues by 
regulating diverse signaling pathways in multidimension, not only because of 
their time-dynamic presenting, also due to their subcellular 
compartmentalization63. Extracellular signaling is translated into changes of 
cAMP and cGMP via different membrane receptors, which subsequently lead to 
multiple cell responses by coordinated activation of cyclic nucleotide-dependent 
protein kinases (PAK and PKG). In the case of the vasculature, they regulate 
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the vascular tone as well as the smooth muscle cell growth64. Physiologically, 
intracellular levels of cAMP and cGMP are controlled in homeostasis between 
their rate of synthesis by adenylyl and guanylyl cyclases and their rate of 
hydrolysis by cyclic nucleotide PDEs respectively63-65(Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: cAMP and cGMP signaling pathway. Prostacyclin, forskolin, arterial natriuretic 
peptide (ANP), brain natriuretic peptide (BNP) and NO, activate adenylate cyclase (AC) or 
guanylate cyclase (GC) to generate cAMP and cGMP from ATP or GTP. The intracellular 
second messenger cAMP and cGMP activate protein kinases (PKA and PKG), which 
phosphorylate downstream proteins and induce cellular responses. Phosphodiesterases 
(PDEs) counter the effects of the stimuli by degrading cAMP and cGMP into 5’AMP and 
5’GMP. (Modified from Schermuly R.T., 2005) 
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1.2.2 Cyclic nucleotide PDEs 
PDEs are a superfamily of enzymes that catalyze the hydrolysis of 3’,5’-cyclic 
nucleotides (3’,5’-cAMP/cGMP) to the corresponding nucleotide 5’-
monophosphates (5’-AMP/GMP)66 (Figure 4). Both cAMP and cGMP are tightly 
regulated by the differentially distributed PDE isoforms in cells to maintain 
physiological functions. 
 
 
 
Figure 4: Cyclic nucleotide hydrolysis by PDEs. (Lugnier, C., 2006)66 
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1.2.2.1 PDE classification 
To date, with 21 genes encoding PDEs identified in the human genome, PDEs 
are subdivided into 11 isoforms (PDE1-PDE11) bases on their amino acid 
sequences, substrate specificities, kinetics, allosteric regulators and inhibitor 
sensitivities63 (Figure 5).  
 
 
Figure 5: Structure of PDE families. The number in parenthesis presents the number of 
genes composing the subfamily. (Conti M & Beavo J. 2007)63 
INTRODUCTION 
- 12 - 
Among those PDEs, PDE4, PDE7, and PDE8 selectively hydrolyze cAMP; 
PDE5, PDE6, and PDE9 are selective for cGMP, while 5 other subfamilies 
(PDE1, 2, 3, 10, and 11) hydrolyze both cyclic nucleotides with varying 
efficiency63, 65-68 (Table 2).  
 
Table 2. Characteristics and distribution of PDEs (Modified from Siuciak J.A., 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2.2 PDE10 
PDE10 is one of the most recently described PDEs and was originally 
characterized as a single member of a dual-substrate gene family in 1999 from 
rodent as well as from human brain69-72. PDE10 transcripts were particularly 
abundant in brain, thyroid and testis. PDE10A is the only isoform of PDE10 
subfamily and contains a consensus PDE catalytic domain in the C-terminus 
and two GAF domains in the N-terminus (Figure 6)69, 70. Different from the GAF 
domain of other PDE families, the GAF domain of PDE10A is the only one that 
binds to cAMP instead of cGMP, which may contribute to the allosteric 
stimulation of PDE10A73, 74.   
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Figure 6: Structure of PDE10A. 
 
 
Existing in multiple splice variant forms, PDE10A has the capacity to hydrolyze 
both cAMP and cGMP; however it has higher affinity for cAMP and is more 
efficient with cAMP as the substrate. The Km for cAMP is approximately 0.05 
µM, whereas the Km for cGMP is 3 µM. In addition, the Vmax for cAMP 
hydrolysis is fivefold lower than for cGMP70. Because of this kinetic pattern, 
cGMP hydrolysis by PDE10A is potently inhibited by cAMP in vitro, suggesting 
that PDE10A functions as a cAMP-PDE and a cAMP-inhibited cGMP-PDE in 
vivo69-71. Papaverine (Figure 7), a naturally occurring plant alkaloid and smooth 
muscle relaxant, can be used as a potent inhibitor of PDE10 exhibiting a low Ki 
of 17 nM as compared to PDE3A/B (Ki = 279 and 417 nM, respectively)75. 
 
 
 
 
 
 
 
 
Figure 7: Structure of papaverine. 
 
 
1.2.2.3 Pathophysiological roles of PDEs in PAH and inhibitors 
Given the intricate expression patterns in distinct tissues and cells, each 
member of PDE family participates in discrete pathophysiological processes 
such as penile erection, asthma, pulmonary hypertension, atherosclerosis, 
heart failure, and inflammation. Furthermore, subcelluar compartment of PDEs 
leads to diverse signal transduction pathways in a space-dynamic and time-
dynamic manner. Therefore, other than fundamental concerns, PDEs are of 
great pharmacological interest64. 
GAF GAF PDE catalytic
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Because of the crucial regulation role of cyclic nucleotides in signaling 
transduction, the concept that PDEs are involved in the pathological process of 
PAH is widely accepted76. Interestingly, expression and activities of PDEs were 
reported to be altered in both experimental and human PAH77. Expression 
profiling of single member of the PDE super family in healthy and remodeled 
pulmonary vasculature revealed that PDE1, PDE3 and PDE5 isoforms are 
differentially regulated78-81. In preclinical and clinical studies we have shown 
that the inhibition of PDE1 by 8MM-IBMX78 and PDE5 by sildenafil57, 80 
stabilizes the second messenger signaling and regulates vascular remodeling, 
vascular tone and optimization of gas exchange. Moreover, in MCT-induced PH 
rats, inhibition of PDE3 and PDE4 isoforms was found to partly reverse the 
pathological inward remodeling in PH82, 83. Given that higher PDEs (PDE7-11) 
were defined more recently, further investigations should be performed to 
understand the possible involvements of higher PDEs in PAH and to improve 
the therapy of PAH by pharmacological PDE inhibitors. 
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2 AIMS OF THE STUDY 
In the pulmonary vasculature, PDEs modulate various signaling pathways via 
the tight control of the cyclic nucleotides. Expression of PDEs is altered in PAH 
and inhibitors of PDEs suppress pulmonary vascular remodeling, while the role 
of the most newly identified PDEs (PDE7-11) has not been investigated yet. 
The substrate specificity, as well as the cellular and subcellular distribution, of 
these newly identified PDEs may provide additional exciting insights in the 
pathophysiology of PAH. Our aim was to identify and characterize cellular 
functions of previously newly identified PDEs in pulmonary vascular remodeling 
in PAH and to offer new selective therapy targets for PAH. In this study, a 
series of study were undertaken as follows: 
 
1. Gene expression pattern of newly identified PDEs both in lung tissue and 
primary PASMCs from control and MCT-induced PH rats. 
2. Changes in enzyme activity as well as localization of the candidate PDE in 
the lung and PASMCs from control and MCT-induced PH rats.  
3. In vitro effects of inhibiting the candidate PDE by siRNA and the 
pharmacological inhibitor. 
4. Molecular mechanisms which may be involved in affecting the cellular 
responses after inhibition of the candidate PDE. 
5. Therapeutic effects of the candidate PDE inhibitor on pulmonary 
hemodynamics and remodeling of MCT-induced PH rats. 
6. Expression and localization of PDE10A in donors and IPAH lungs.  
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals, reagents and kits 
Most of the chemicals were purchased either from Sigma-Aldrich (USA) or from 
Merck (Germany). The rests are listed as follows.  
Product       Company 
Baytril (quinolone antibiotic)    Bayer, Gemany 
Bovine serum albumin  powder   Serva, Germany 
Bovine serum albumin solution (2 mg/ml)   Bio-Rad, USA 
cAMP EIA kit      Cayman Europe, Estonia 
[3H]-cAMP       Amersham, USA 
DAPI        Dakocytomation, USA 
Dc protein assay kit      Bio-Rad, USA 
DEPC water       Roth, Germany 
Digest All 2 (trypsin)      Vector, UAS 
Domitor (Medetomidinhydrochlorid, 100 mg/ml) Pfizer, USA 
DNA Ladder (100 bp, 1 kb)    Promega, USA 
Enhanced chemiluminescence (ECL) kit  Amersham, USA 
Fluorescent mounting medium    Dakocytomation, USA 
GoTaq® PCR Core System I    Promega, USA 
ImProm-IITM Reverse Transcription System  Promega, USA 
Ketavet (Ketaminhydrochlorid, 100 mg/ml)  Pharmacia, USA 
Milk powder       Roth, Germany 
N,N’-Methylene-bis-Acrylamide solution, Rotiphorese gel 30 
Roth, Germany 
NovaRED substrate kit     Vector, USA 
Protein rainbow markers     Amersham, USA 
QAE Sephadex A-25     Amersham, USA 
RIPA buffer       Santa Cruz, USA 
RNase Away Molecular Bioproducts, 
USA 
Saline (NaCl 0.9%)      B. Braun, Germany 
Scintillation solution (Rotiszint®eco plus)  Roth, Germany 
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SDS Solution, 10% w/v     Promega, USA 
Sildenafil       Pfizer, USA 
SYBR® GreenER™ qPCR SuperMixes Universal kit Invitrogen, USA 
[3H]-thymidine (1 mCi/ml)     Amersham, USA 
Tris-HCl 0.5 M, pH 6.8     Amresco SOLON, USA 
Tris-HCl 1.5 M, pH 8.8     Amresco SOLON, USA 
Trizol        Invitrogen, USA 
UltraPure water      Cayman Europe, Estonia 
X-tremeGENE siRNA Transfection Reagent  Roche, Germany 
 
3.1.3 Cell culture medium 
DMEM/F12, Opti-MEM and HBSS are purchased from Invitrogen (USA). Fetal 
bovine serum is from Biowest (Germany). The rest including PBS, L-glitamine, 
penicillin/streptomycin and Trypsin/EDTA are all purchased from PAN 
(Germany). 
 
3.1.4 Antibodies 
Primary antibody      Company 
Mouse anti-αSMA monoclonal antibody   Sigma-Aldrich, USA 
Mouse anti-GAPDH monoclonal antibody  Sigma-Aldrich, USA 
Rabbit anti-PDE10A polyclonal antibody  Novus, USA 
Rabbit anti-PDE10A polyclonal antibody  Scottish Biomedical, UK 
Rabbit anti-CREB polyclonal antibody   Millipore, USA 
Rabbit anti-p-CREB (Ser133) polyclonal antibody Millipore, USA 
 
HRP-conjugated secondary antibody   Company 
Rabbit anti-mouse IgG     Sigma-Aldrich, USA 
Goat anti-rabbit IgG     Pierce, USA 
  
Fluor-conjugated secondary antibody  Company  
Alexa Fluor® 488 goat anti-rabbit IgG   Invitrogen, USA 
FITC conjugated goat anti-rabbit IgG   Invitrogen, USA 
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3.1.5 Oligonucleotides 
Small interfering RNA (siRNA) 
siRNA pairs were designed and purchased from Eurogentec (Belgium). The 
siRNA duplex is made of two strands of 19 complementary RNA bases with 
3’dTdT overhangs (Table 3). The negative control si-scramble is a duplex with 
a random sequence which does not march to any genes. 
Table 3: Sequence for PDE10 siRNA pair 
Gene  siRNA Sequence 
Sense strand 5´  GGACAGCUUGGAUUCUACA  3´ rat PDE10A 
Antisense strand 5´  UGUAGAAUCCAAGCUGUCC  3´ 
 
Primers 
Primer oligonucleotides were all purchased from Metabion (Germany). The 
sequences for realtime-PCR are listed in Table 4 and the sequences for 
standard PCR are listed in Table 5. 
Table 4: Primer sequences for quantitative realtime-PCR 
Gene (rat)  Primer Sequence 
Forward 5´  ATCAGCCACCCAGCCAAA  3´ PDE1A 
113bp Reverse 5´  GGAGAAAACGGAAGCCCTAA  3´ 
Forward 5´  CACAAGCCCAGAGTGAACC  3´ PDE3A 
123bp Reverse 5´  TGGAGGCAAACTTCTTCTCAG  3´ 
Forward 5´  GTCGTTGCCTTGTATTTCTCG  3´ PDE3B 
103bp Reverse 5´  AACTCCATTTCCACCTCCAGA  3´ 
Forward 5´  GAAGAGGTTCCCACCCGTA  3´ PDE7A 
85bp Reverse 5´  CTGATGTTTCTGGCGGAGA  3´ 
Forward 5´  GGCTCCTTGCTCATTTGC  3´ PDE7B 
99bp Reverse 5´  GGAACTCATTCTGTCTGTTGATG  3´ 
Forward 5´  TGGCAGCAATAAGGTTGAGA  3´ PDE8A 
97bp Reverse 5´  CGAATGTTTCCTCCTGTCTTT  3´ 
Forward 5´  CTCGGTCCTTCCTCTTCTCC  3´ PDE8B 
147bp Reverse 5´  AACTTCCCCGTGTTCTATTTGA  3´ 
Forward 5´  GTGGGTGGACTGTTTACTGGA  3´ PDE9A 
107bp Reverse 5´  TCGCTTTGGTCACTTTGTCTC  3´ 
Forward 5´  GACTTGATTGGCATCCTTGAA  3´ PDE10A 
115bp Reverse 5´  CCTGGTGTATTGCTACGGAAG  3´ 
Forward 5´  CCCAGGCGATAAATAAGGTTC  3´ PDE11A 
87bp Reverse 5´  TGCCACAGAATGGAAGATACA  3´ 
Forward 5´  ATGTCCGGTAACGGCGGC  3´ PBGD 
135bp Reverse 5´  CAAGGTTTTCAGCATCGCTAC  3´ 
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Table 5: Primer sequences for standard PCR 
Gene (rat)  Primer Sequence 
Forward 5´  CGATAGAACACGGCATCATC  3´ αSMA 
525bp Reverse 5´  CATCAGGCAGTTCGTAGCTC  3´ 
Forward 5´  GGGTGAAACCCCACGACATT  3´ Calponin 
552bp Reverse 5´  CGTCCAGCTCTGGATATTCC  3´ 
Forward 5´  GCCAGAACAAGGAACTCCGA  3´ SM-MHC 
529bp Reverse 5´  GTTCCATTGAAGTCTGAGTCCC  3´ 
Forward 5´  GTCACCAGGGCTGCCTTCT  3´ GAPDH 
121bp Reverse 5´  CATTGAACTTGCCGTGGGTA  3´ 
 
 
3.1. 6 Equipments          
Equipment      Company                                                          
BioDoc Analyzer     Biometra, USA 
Cell culture incubator, Hera Cell   Heraeus, Germany 
Electrophoresis chamber    Biometra, USA 
Fluorescence microscope    Leica, Germany 
Freezer (+4˚C, -20 ˚C, -80 ˚C)   Bosch, Germany 
Infinite® 200 microplate reader   Tecan, Switzerland 
Inolab PH meter     WTW, Germany 
Light microscope     Hund, Germany 
Liquid scintillation counter, LS 6500  Beckmann, USA 
Multifuge centrifuge     Heraeus, Germany 
Mx3000P® QPCR system machine  Stratagene, USA 
Spectrophotometer      NanoDrop Technologies, USA 
PCR-thermocycler     Biometra, Germany 
Pipetboy and pipettes    Eppendorf, USA 
Power supply     Biometra, USA 
Precellys®24 homogenizer   Bertin Technologies, France  
Shaker      Biometra, USA 
Water bath for cell culture    Medingen, Germany 
Water bath for tubes    HLC, Germany 
Western blot unit     Biometra, USA 
Vortex machine     VWR, Germany 
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3.1. 7 Other materials 
Falcon tubes, PCR tubes, glass pipettes and cell culture dishes and plates 
were purchased from Greiner Bio-One (Germany). Others are as listed below. 
Material      Company 
96-well microplate     Corning, USA 
AGFA cronex 5 medical X-ray film  AGFA, Belgium 
Chromatography column    Bio-Rad, USA 
Film casette      Kodak, USA 
Filter tips (10, 100, 1000µl)   Nerbe plus, Germany 
Gel blotting paper     Whatman, USA 
Nitrocellulose membrane    Pall Corparation, USA 
Osmotic minipump (2 mL)    Durect Corparation, USA 
Precellys bead mill sample tube   Bertin Technologies, France 
Radiographic film hypersensitive   Amersham, USA 
Santilation tube     Nerbe plus, Germany 
Tips (10, 100, 1000µl)    Eppendorf, USA 
Reaction tube     Sarstedt, Germany 
Real time tube     Thermo Fisher, USA 
Tissue culture chamber slide   BD Falcon, USA 
 
3.2 Methods 
3.2.1 Animals  
Adult male Sprague-Dawley rats (250-300 g in body weight) were purchased 
from Charles River Laboratories (Sulzfeld, Germany). The experiments were 
performed in accordance with the National Institutes of Health Guidelines on 
the Use of Laboratory Animals. Both the University Animal Care Committee and 
the Federal Authorities for Animal Research of the Regierungspräsidium 
Giessen (Hessen, Germany) approved the study protocols. 
 
3.2.1.1 Monocrotaline-induced pulmonary hypertensive rat model 
Alkaloid monocrotaline was dissolved in 1 mol/L HCl and then adjusted to pH 
7.4 with 1 mol/L NaOH, resulting in a clear solution with a final concentration of 
20 mg/ml58. Rats were randomized for a one-shot subcutaneous (s.c.) injection 
of 60 mg/kg MCT to induce pulmonary hypertension, or an injection of the same 
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volume of saline to be as a control. Drinking water supplemented with antibiotic 
Baytril was given to MCT-injected rats for 2 weeks at the second day of MCT 
injection. Both of the control and MCT rats were kept up to 4 weeks for cell 
isolation, while for in vivo experiments rats were subjected to hemodynamic 
studies after 5 week of MCT injection.  
 
3.2.1.2 Experimental groups 
The animals were classified into the following three groups: 1) rats injected with 
saline and sacrificed after 35 days (Control, n=9); 2) MCT-injected rats 
subjected to minipump implantation from day 21 to day 35 with saline 
(MCT[35d]/saline, n=8); 3) MCT-injected rats subjected to minipump 
implantation from day 21 to day 35 with 5 mg/ml papaverine 
(MCT[35d]/papaverine, n=8). 
 
3.2.1.3 Surgical preparation and hemodynamic measurements 
Three weeks after MCT injection, rats were subjected to papaverine treatment 
for 2 weeks by implantation of osmotic minipumps (Alzet Model 2 mL). At day 
21, after the rat was anaesthetized with an intraperitoneal injection (i.p.) of 
ketamine (9 mg/kg body mass) and medetomidine (100 µg/kg body mass), a 
minipump filled with 2 ml saline or with 2 ml papaverine (5 mg/ml) was 
implanted in the dorsal subcutaneous region under sterile conditions and a 
tunneled catheter (PE 50 tubing) was inserted into the left jugular vein. The 
releasing rate of the minipump is 5 µl per hour. After wound-closing with 
sutures, the rats were recovered from anesthesia by an intraperitoneal injection 
of naloxon and atipazemol (50 and 100 µg/kg body mass). At the end of the 
treatment, the rats were anesthetized with an intraperitoneal injection (i.p.) of 
ketamine (9 mg/kg body mass) and medetomidine (100 µg/kg body mass), 
followed by an intramuscular (i.m.) injection of heparin (50 IU/kg body mass) to 
measure the hemodynamic parameters. The rats were then tracheotomized 
and ventilated at a frequency of 60 breaths/min, with a positive end expiratory 
pressure at 1 cm H2O throughout. To measure right ventricular pressure, a right 
heart catheter (PE 50 tube) was inserted through the right jugular vein and to 
measure arterial pressure a polyethylene catheter was inserted into the left 
carotid artery84. 
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3.2.1.4 Histological assessment of the degree of muscularization of small 
pulmonary arteries 
Three µm lung sections from blocks fixed in 3% paraformaldehyde solution 
were applied to a double staining with the anti-von Willebrand-factor antibody 
(1:900) and anti α-SMA antibody (1:900) for the analysis of small peripheral 
pulmonary artery muscularization. In each rat, 80 to 100 intraacinar arteries 
(20-50 µm) were categorized by the software as full muscularized,  partially 
muscularized, or nonmuscularized, as previously described84. 
 
3.2.1.5 Tissue preparation 
After the hemodynamic measurement, the lungs were flushed with saline via 
the pulmonary artery, the left lobes were snap frozen in liquid nitrogen and 
stored at -80°C for molecular studies while the right lobes were fixed in 3% 
paraformaldehyde solution for histological studies. Lungs for pulmonary artery 
isolation were freshly dissected and immersed in ice-cold Hank’s balanced salt 
solution (HBSS) containing penicillin/streptomycin (P/S, 100 units/ml).    
 
3.2.2 Isolation of pulmonary arterial smooth muscle cells (PASMCs) 
Rat PASMCs were cultured from peripheral small pulmonary artery explants as 
previously described85. To isolate PASMCs, the freshly dissected rat lung was 
removed of lung parenchyma and interstitial tissues around the arteries until the 
small pulmonary arteries were completely exposed under a dissecting 
microscope. Then the adventitia layer was removed by micro-dissection. Artery 
segments were cut open along the longitudinal axis and the endothelium was 
gently removed by scraping the luminal surface. The arteries were minced into 
1 mm2 explant pieces and maintained in Dulbecco's modified Eagle's 
medium/F12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 
P/S (100 units/ml) and 2 mM L-glutamine. After 5 days PASMCs started to 
migrate from the explants, followed by 10 days of culturing. The morphology of 
PASMCs was observed under contrast microscopy and the early passages 
(passage 2-5) were used for all experiments. Every experiment in the following 
was performed with primary PASMCs isolated from at least 3 individual rats. 
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3.2.3 RNA interference 
Transient transfection of siRNA was performed with X-tremeGENE siRNA 
transfection reagent according to the manufacturer’s protocols. PASMCs were 
subcultured to 40% confluence in antibiotic-free DMEM supplemented with 10% 
FBS and 2 mM L-glutamine. siRNA and transfection reagent were diluted in 
opti-MEM and mixed within 5 min after dilution at a final ratio of 4:1 
(transfection reagent µl to siRNA µg). After incubation for 20 min at RT, 
transfection of 100 nM siRNA was performed in opti-MEM for 5 h, followed by 
culturing in DMEM supplemented with 10% FBS and 2 mM L-glutamine up to 
24 h (for RNA isolation) or 48 h (for protein isolation, enzyme immunoassay 
and proliferation assay). The RNA interference was well established and 
repeated at least three times. 
 
3.2.4 Polymerase chain reaction (PCR) 
3.2.4.1 RNA isolation 
Total RNA from tissues or cells was extracted using Trizol according to the 
manufacturer's instructions. 50 mg lung tissue was applied to 1 ml Trizol and 
homogenized by Precellys24 homogenizer, or 2×106 PASMCs were collected 
in 1 ml Trizol. Trizol lysates were kept at RT for 5 min to dissociate the RNA 
from histone proteins. Then add 0.2 ml chloroform, vigorously mix for 15 sec 
and centrifuge under 12000 rpm at 4°C for 30 min. After that, the transparent 
upper layer was carefully transferred to a new tube and gently mixed with 0.5 
ml 2-propanol. After 15 min the mixture was centrifuged under 12000 rpm at 
4°C for 15 min and the RNA pellet was washed with 1 ml 75% ethanol and 
dried in the air. RNA was dissolved in DEPC-water and stored at -80°C. The 
concentration and quality of RNA were estimated by NanoDrop 
spectrophotometer.  
 
3.2.4.2 Reverse transcription-PCR (RT-PCR)   
cDNA was synthesized by a two-step RT-PCR using ImProm-II™ reverse 
transcription system according to the manufacturer’s instructions. 1 µg RNA in 
5 µl reaction A was denatured at 70°C for 5 min, followed by a quick chill for 5 
min and addition of 15 µl reaction B. The reverse transcription reactions were 
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subjected to cDNA synthesis by firstly annealing at 25°C for 5 min and 
incubating at 42°C for 60 min, followed by thermal inactivation of reverse 
transcriptase at 70°C for 15 min. The cDNA was stored at -20°C. 
 
Reaction A component Volume Final concentration
Total RNA, 1µg/ul 1 µl 1 µg/20µl 
Oligo(dT)15 primer, 0.5 µg/µl 1 µl 1 µg/20µl 
 
Reaction B component Volume Final concentration
ImProm-II™ 5X reaction buffer 4 µl 1 X 
MgCl2, 25 mM 2 µl 2.5 mM 
dNTP mix, 40 mM 1 µl 2 mM 
RNasin® ribonuclease inhibitor 1 µl 20 u/20µl 
ImProm-II™ reverse transcriptase 1 ul 0.5 u/20µl 
Nuclease-free water to a final volume 15 µl  
 
 
3.2.4.3 Standard PCR 
cDNA GoTaq® PCR core system I was applied for standard PCR using the 
program as follows. The annealing temperature is 58°C for GAPDH, αSMA (α-
smooth muscle actin), SM-MHC (smooth muscle-myosin heavy chain) and 
Calponin. PCR reaction mixture was made as listed.  
 
PCR reaction component Volume Final concentration
cDNA 2 µl 0.5 µg/25µl 
MgCl2, 25mM 2 µl 2 mM 
dNTP mix, 40mM 0.5 µl 200 µM 
Upstream primer, 10 µM 0.75 µl 0.3 µM 
Downstream primer, 10 µM 0.75 µl 0.3 µM 
5X Green GoTaq® flexi buffer 5 µl 1.0 X 
GoTaq® DNA polymerase 0.25 µl 1.25 u/25µl 
Nuclease-free water to a final volume  25 µl  
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PCR programm Temperature Time Cycle 
Initial denaturation 95°C 2 min 1 
Denaturation 95°C 1 min  
Annealing Variable 1 min 30 
Extension 72°C 1 min/kb  
Final extension 72°C 5 min 1 
Soak    4°C indefinite 1 
 
 
3.2.4.4 Quantitative realtime- PCR (qRT-PCR ) 
The intron-spanning primer pairs were designed using the Primer3 program 
and are shown in Table 3. Primers were cross checked to insure the specificity 
by blasting to the whole genome. The product size is controlled within the range 
of 80 bp-150 bp.  
 
qRT-PCR reaction component Volume Final concentration
cDNA 2 µl 0.2 µg/25µl 
MgCl2, 25 mM 1 µl 1 mM 
ROX, 25 µM 0.1 µl 100 µM 
Upstream primer, 10 µM 0.5 µl 0.2 µM 
Downstream primer, 10 µM 0.5 µl 0.2 µM 
2X SYBR® GreenER™ SuperMix 
Universal buffer 12.5 µl 1.0 X 
Nuclease-free water to a final volume  25 µl  
 
qRT-PCR was performed on a Mx3000P® QPCR system machine using 
SYBR® GreenER™ qPCR SuperMixes Universal kits according to 
manufacturer’s instructions. For the negative control, the cDNA was omitted. 
The annealing temperature for every gene is 58°C. By using the MxPro™ 
QPCR software, a dissociation curve was generated for each gene to ensure a 
single product amplification and the threshold cycle (Ct values) for each gene 
was determined. The comparative 2-∆∆Ct method was used to analysis mRNA 
fold changes between control and MCT, which was calculated as Ratio = 2-(∆Ct 
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control-∆Ct MCT) where Ct is the cycle threshold, and ∆Ct (Ct target－Ct reference)  is the 
Ct value normalized to the reference gene Porphobilinogen Deaminase (PBGD) 
obtained for the same cDNA sample. Each reaction was run in duplicate and 
repeated three times independently. The calculated 2-∆∆Ct was transformed into 
a percentage using the control as 100% to show the mRNA expression 
difference. 
 
qRT-PCR programm Temperature Time Cycle 
Activation 95°C 10 min 1 
Denaturation 95°C 30 sec  
Annealing 58°C 30 sec 40 
Extension 72°C 30 sec  
Denaturating 95°C 1 min  
Dissociation curve 55-95°C indefinite 1 
Soak    4°C indefinite 1 
 
 
3.2.4.5 Agarose gel electrophoresis of DNA 
PCR products together with DNA ladder (100bp, 1kb) were loaded on 1.5% 
agarose gel containing 1 µg/ml ethidium bromide and were run in tris-acetate-
EDTA (TAE) buffer at 100 V until separated. The DNA bands were detect by 
UV illumination and captured by BioDoc Analyzer. 
 
TAE buffer component Final concentration 
Tris-HCl 40 mM 
Acetic acid 40 mM 
EDTA , 0.5 M, pH 8.0    1 mM 
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3.2.5 Western blotting 
3.2.5.1 Protein isolation 
Total protein was extracted in RIPA buffer containing 1XTBS, 1% Nonidet P-40, 
0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide. PMSF, 
proteinase inhibitor cocktail and sodium orthovanadate (10µl each in 1 ml RIPA) 
were added to RIPA freshly before use. 100 mg lung tissue homogenized in 
800 µl RIPA or 2×106 PASMCs in 250 µl RIPA was centrifuged under 12000 
rpm for 30 min at 4°C and the supernatants were stored at -80°C. 
 
3.2.5.2 Protein concentration analysis 
A series of bovine serum albumin (BSA) solution from 0.2-1.6 mg/ml were used 
as standard. The protein samples were pre-diluted into the range of the 
standard and the concentration of each sample was double estimated by Dc 
protein assay kit based on the method of Bradford using a microplate reader. 
 
3.2.5.3 SDS-polyacrylamide (SDS-PAGE) gel electrophoresis 
Protein samples of the same concentration were mixed with 5× SDS gel-
loading buffer at a ratio of 4:1 (v/v) and denatured at 100°C for 5 min. Protein 
samples (30 µg for PDE10A, CREB and pCREB; 15 ug for GAPDH) or rainbow 
marker were loaded in the wells of 10% SDS-PAGE gel and run at 100-130 v 
for 2-3 hours to separate. Buffers are listed as follows.  
 
5×SDS gel-loading buffer component Final concentration 
Tris-Cl (2 M, pH 6.8) 375 mM 
SDS 10% (w/v) 
Glycerol   50% (v/v) 
β-Mercaptoethanol 12.5% (v/v) 
Bromophenol blue 0.02% (w/v) 
 
Running buffer component Final concentration 
Tris-HCl 25 mM 
Glycine 192 mM 
SDS 10% (w/v) 0.1% (w/v) 
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Resolving gel (10%) component Volume Final concentration 
Tris-Cl (1.5 M, pH 8.8) 0.625 ml 375 mM 
Acrylamid 30% (w/v) 0.5 ml 10% (w/v) 
SDS 10% (w/v) 25 µl 0.1% (w/v) 
APS 10% (w/v) 12.5 µl 0.05% (w/v) 
 
Stacking gel (6%) component Volume Final concentration 
Tris-Cl (0.5 M, pH 6.8) 1.5 ml 375 mM 
Acrylamid 30% (w/v) 2 ml 10% (w/v) 
SDS 10% (w/v) 60 µl 0.1% (w/v) 
APS 10% (w/v) 30 µl 0.05% (w/v) 
TEMED 6 µl 0.1% 
H2O    2.4 ml  
 
3.2.5.4 Immunoblotting 
The proteins separated on the SDS-PAGE were transferred to nitrocellulose 
membrane using an electrophoretic transfer machine. After being soaked in 
blocking buffer for 1 h at RT, membranes were probed with specific primary 
antibodies (rabbit polyclonal anti-PDE10A antibody,1:2000; rabbit polyclonal 
anti-CREB antibody, 1:000; rabbit polyclonal anti-phospho-CREB(Ser133) 
antibody, 1:000; mouse monoclonal anti-GAPDH antibody, 1:5000) overnight at 
4°C. After wash with TBST for 3 times, horse radish peroxidase (HRP)-
conjugated secondary antibodies (anti-rabbit, 1:50000; anti-mouse, 1:50000) 
were applied to the membranes respectively for 1 h at RT. After washing, the 
blots were developed with an enhanced chemiluminescence (ECL) kit for 5 min 
and chemiluminescence signal was captured on an X-ray film. Each blot was 
repeated twice independently with representative blots shown. 
 
Blotting buffer Final concentration 
Tris-HCl 50 mM 
Glycine 40 mM 
Methanol  20% (v/v) 
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TBST buffer ( pH 7.6) component Final concentration 
Tris-HCl 20 mM 
NaCl 137 mM 
Tween 0.1% (v/v) 
Blocking buffer component Final concentration 
Non-fat milk 5% (w/v) in TBST 
 
 
3.2.6 Immunohistochemistry 
Three µm lung sections were cut from lung blocks fixed in 3% 
paraformaldehyde solution. After deparaffinization in xylene and rehydration in 
a series of grade-decreasing ethanol solutions followed by phosphate-buffered 
saline (PBS), the antigen retrieval was achieved by 0.25% trypsin for 15min at 
37°C. Then a NovaRED horseradish peroxidase (HRP)-substrate kit was 
applied for immunohistochemistry staining according to the manufacturer’s 
instructions. After being treated with 3% hydrogen peroxide for 20 min to block 
the endogenous peroxidases and serum blocking for 1 h, the sections were 
subjected to anti-PDE10A polyclonal antibody (1:200, in 10% BSA) overnight at 
4°C. After washing, the corresponding secondary antibody conjugated with 
HRP was applied for 30 min. After washing, color development was carried out 
with a substrate/chromogen mixture, followed by counterstaining with 
hematoxylin. The sections were examined under a Leica DM 2500 microscopy 
using Leica QWin imaging software. Sections from 4 rats of each group were 
stained with the representative staining shown. The sections without secondary 
antibodies were negative controls. 
 
3.2.7 Immunocytochemistry 
Rat PASMCs grown on 8-well chamber slides were fixed with the ice-chilled 
acetone-methanol mixture (1:1) for 10 min at 4°C. After washing with PBS, the 
fixed cells were sequentially incubated with blocking buffer (3% BSA in PBS）
for 1 h at RT, and then the primary antibody against αSMA (1:1000 in blocking 
buffer) for 1 h at RT or against PDE10A (1:200 in blocking buffer) overnight at 
4°C. After the primary antibodies, cells were washed 5 times with PBS and 
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subjected to FITC-conjugated anti-mouse or Alexa Fluor® 488 anti-rabbit 
secondary antibody (1:1000 in blocking buffer) for 1 h at RT in dark. Then cells 
were washed 5 times with PBS and counterstained for nuclei with DAPI (500 
ng/ml in blocking buffer) for 3 min. After washing with PBS, the upper chamber 
was removed and the slide was covered with a cover slide using the fluorescent 
mounting medium. The staining was visualized using a Leica DMLA 
fluorescence microscope and Leica QWin imaging software. PASMCs from 3 
individual rats of each group were stained with the representative staining 
shown. The wells without primary antibodies were negative controls. 
 
3.2.8 PDE inhibitors 
3-Isobutyl-1-methylxanthine (IBMX) was used as a nonspecific PDE inhibitor. 8-
Methoxymethyl-IBMX (8MM-IBMX), erythro-9-(2-Hydroxy-3-nonyl) adenine 
(EHNA), milrinone, rolipram, sildenafil and papaverine were used as relatively 
selective PDE inhibitors for PDE1, PDE2, PDE3, PDE4, PDE5 and PDE10 
respectively.  
 
3.2.9 PDE activity assay 
cAMP specific PDE activities were determined by a modified method of 
Thompson and Appleman and Bauer and Schwabe86, 87. The PASMC protein 
was extracted by RIPA buffer and equalized to the same concentration for use. 
The reactions were performed with 10 µg protein in 100 µl reaction buffer at 
37°C for 15 min. Then the samples were boiled for 3 min, subsequently cooled 
for 5 min and incubated with 25 µl Crotalus atrox snake venom (20 mg/ml) for 
15 min at 37°C. After being chilled on ice, the samples were applied to QAE 
Sephadex A-25 mini-chromatography columns and eluted with 1ml ammonium 
formate (30 mM, pH 7.5). The elutes were collected in 2 ml scintillation solution 
and counted by a beta-counter giving a CPM (counts per minute) value. Data 
were expressed as picomoles of cAMP per minute per milligram of protein. 
(pmol cAMP / minute / mg protein). Each assay was performed in triplicate and 
repeated twice independently. 
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PDE activity reaction buffer Final concentration 
HEPES (1 M, pH 7.6) 40 mM 
MgCl2 5 mM 
BSA 1 mg/ml 
cAMP  1 µM 
[3H]-cAMP (1 mCi/ml) 1 µCi/ml 
 
 
3.2.10 cAMP enzyme immunoassay (EIA) 
Intracellular cAMP content of PASMCs was determined by a competitive non-
acetylated EIA, using a specific cAMP EIA Kit according to the manufacturer's 
instructions. At the end of culture, cells were washed twice with PBS and lysed 
in 0.1 M HCl at RT for 20 min. The lysates were collected and centrifuged 
under 12000 rpm for 30min at 4°C. The supernatant was transferred to a new 
tube and stored at -80°C. The protein concentration was estimated by the Dc 
protein assay as described before and equalized to 0.3 µg/µl for use. 50 µl 
protein samples or standard solutions were incubated in dark with 50 µl tracer 
and 50 µl antibody overnight at 4°C. After washing 5 times, the plate was 
incubated with Ellman’s solution for 90-120 min at RT with gentle shaking. The 
plate was read at a wavelength of 405 nm and the concentration was calculated 
by the ready-made Cayman EIA Double workbook. The standard curve was 
made as a plot of the %B/B0 value (%Bound/Maximum Bound) vs concentration 
of a series of known standards using a linear (y) and a log (x) axis. Using the 4-
parameter logistic equation obtained from the standard curve, the cAMP 
concentration of samples was determined and given as nmol/mg protein. Each 
sample was performed in duplicate and repeated twice.   
 
3.2.11 Proliferation assay 
PASMC proliferation was achieved by [3H]-thymidine incorporation assay as 
described previously58. PASMCs (around 1×104 cells/well) were seed on 48-
well plates and the following day the medium was substituted with DMEM/F12 
containing 0.1% FBS with or without siRNA to render the cells quiescent. After 
24-h serum starvation, cells were induced to cell cycle reentry by 10% FBS 
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together with different PDE inhibitors for 24 h. The concentration of PDE 
inhibitors used for proliferation assay was pre-proved for PDE selectivity 
according to the previous reports83, 88. During the last 4 h of FBS stimulation, 10 
µl [3H]-thymidine (0.01 µCi/ml) was added to 250 µl medium to incorporate into 
the DNA. Cells were then washed twice with 500 µl chilled HBSS, fixed with 
250 µl ice-cold methanol for 15 min at 4°C and then precipitated by 250 µl 10%  
trichloroacetic acid (TCA) for 15 min at 4°C. After washing with water, samples 
were finally lysed in 0.1 M NaOH, transferred into 4 ml scintillation solution and 
counted by a beta counter giving a CPM value. All labeling was performed on 
quadruplicate cultures and repeated twice independently. The proliferation of 
PASMCs under 10% FBS stimulation is shown as a percentage taking the CPM 
of unstimulated PASMCs under 0.1% FBS as 100%. 
 
3.2.12 Statistical analysis 
Data are expressed as mean and standard error of mean (SEM). All statistical 
analysis was performed with Student’s t-test between two groups or with one-
way ANOVA and Newman-Keuls post-hoc test for multiple comparisions, as 
appropriate. Difference between groups is considered significant when P＜0.05. 
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4 RESULTS 
4.1 Primary PASMCs isolation and characterization  
Small pulmonary arteries (Figure 8A, in white squares) dissected from the rat 
lung were subjected to PASMC isolation. Primary PASMCs in early passages 
exhibited typical spindle-shape morphology and grew with a “hill-and-valley” 
pattern (Figure 8B). To ensure the property and purity of isolated PASMCs, the 
presence of key vascular smooth muscle cell markers were assessed by semi-
quantitative PCR or by immunocytochemistry. Vascular SMC phenotype genes 
including αSMA, SM-MHC and calponin are all equally expressed in cells 
isolated from control and MCT-PH rats on mRNA level (Figure 8C), which is 
confirmed by a 98% positive staining in cells against αSMA (Figure 8D). 
 
A)                                                             B) 
 
 
 
 
 
 
C)                 D) 
 
  
 
 
 
 
 
Figure 8: Primary PASMCs cultured from small pulmonary arteries. A) Pulmonary 
artery branches freshly dissected from a rat lung. The small artery (less than 0.5 mm in 
diameter) in the white square magnified in the right corner was used for PASMC isolation. 
B) Morphology of rat PASMCs with a 90% confluence at passage 1 observed by a phase-
contrast microscope. C) mRNA expression of vascular SMC phenotypic genes in both 
control and MCT PASMCs by semi-quantitive PCR. D) Immunocytochemistry staining of 
isolated cells against αSMA. PASMCs showed a positive staining of αSMA fibers in green 
with nucleus stained blue by DAPI.  
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4.2 Profiling of PDE7-11 expression in rat lungs and PASMCs 
4.2.1 Expression of PDE711 isoforms in rat lung tissue 
Expression of newly identified PDEs (PDE7-11) in lungs from both control rats 
and MCT-PH rats was investigated by qRT-PCR. In rat lung tissue, PDE7-11 
isoforms were all expressed on mRNA level. Out of those PDEs, PDE7A, 
PDE7B and PDE10A were significantly upregulated (264.7±16.2%, 
230.7±25.3% and 140.6±9.5% of control respectively), while PDE8B was 
downregulated (50.2±6.9% of control) in MCT-PH lungs as compared to control 
lungs. PDE8A, PDE9A and PDE11A were shown on the same level in both 
groups (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: mRNA expression of PDE7-11 isoforms in rat lung tissue. Relative mRNA 
levels of PDE7-11 in lung homogenates from control rats (grey bars) and from 4-week 
MCT rats (black bars) were shown as a percentage of control by qRT-PCR after 
normalization to PBGD. *P < 0.05, **P < 0.01, ***P < 0.001 vs control lungs. n = 4 in each 
group. Values are expressed as mean ± SEM. 
 
 
4.2.2 Expression of PDE7-11 isoforms in rat PASMCs 
In the isolated PASMCs, we discovered that only PDE7A, PDE7B, PDE8A, 
PDE10A and PDE11A are present, with an increase of PDE7A (259.4±11.1% 
of control) and PDE10A (254.9±36.9% of control) in MCT-PH PASMCs as 
compared to control PASMCs (Figure 10). 
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Figure 10: mRNA expression of PDE7-11 isoforms in rat PASMCs. Relative mRNA 
levels of PDE 7-11 in PASMCs from control rats (grey bars) and from 4-week MCT rats 
(black bars) were shown as percentage of control by qRT-PCR after normalization to 
PBGD. **P < 0.01 vs control PASMCs. n = 4 in each group. Values are expressed as 
mean ± SEM. 
 
 
4.3 PDE10A localization and expression in pulmonary vasculature 
4.3.1 PDE10A localization in rat lung 
Since PDE10A was the first time described in the adult rat lung, 
immunohistochemistry was performed in lung sections to verify PDE10A 
expression pattern in rat lung. A stronger immunoreactivity of PDE10A was 
observed in lung specimens from MCT-PH rats, suggesting that the site-
specific change of PDE10A occurred especially in the medial layer of the 
pulmonary arteries (Figure 11 c,d). In contrast, only weak expression of 
PDE10A was detected in pulmonary vessels of control rat lung (Figure 11 a,b). 
In addition, immunoreactivity against PDE10A was also noted in bronchial 
SMCs of the small airways. 
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Figure 11: Immunohistochemistry staining of PDE10A in rat lung sections. 
Representative staining of lung sections from control rats (a,b) and MCT rats (c,d) shows 
dominant PDE10A expression in rat PASMCs. PA means pulmonary artery. Scale bar: 20 
µm. 
  
 
4.3.2 PDE10A expression is exclusively induced in pulmonary vasculature 
To investigate whether if PDE10A induction is specific in remodeled pulmonary 
vasculature, we examined PDE10A expression in the pulmonary artery and in 
the systemic arteries including aortic artery and femoral artery. qRT-PCR data 
showed a 2-fold  increase of PDE10A mRNA expression in the pulmonary 
artery of MCT-PH rats compared to control rats, with no changes in either the 
aortic artery or femoral artery (Figure 12).  
 
 
 
 
 
 
 
 
 
Figure 12: PDE10A mRNA expression in pulmonary and systemic vessels.  qRT-PCR 
analysis of PDE10A expression in the pulmonary artery (P.A.), aortic artery (A.A.) and 
femoral artery (F.A.) from control rats (grey bars) and 4-week MCT rats (black bars), 
shown as a percentage of control after normalization to PBGD. **P < 0.01 vs control. n = 4 
in each group. Values are expressed as mean ± SEM. 
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4.4 PDE10A expression, activity and localization in rat PASMCs 
4.4.1 Protein expression of PDE10A in rat PASMCs 
In corroboration of increased PDE10A expression on the immunoreactivity level 
and the mRNA level in pulmonary vessels, immunoblotting demonstrated a 1.6-
fold increase of PDE10A in MCT-PH PASMCs compared to control PASMCs 
(Figure 13A and 13B). 
 
A)                     B) 
 
 
 
 
 
 
Figure 13: PDE10A protein expression in rat PASMCs. A) Representative immunoblots 
against PDE10A with GAPDH as a loading control. B) Densitometric quantification of 
PDE10A expression in PASMCs is shown as a ratio by normalization to GAPDH in a bar 
graph. *P < 0.05 vs control PASMCs.  n = 3 in each group. Values are expressed as mean 
± SEM. 
 
 
4.4.2 Enzyme activity of PDE10A in PASMCs 
To assess the enzymatic activity of PDE10A, cAMP hydrolyzing PDE activity 
assays were performed. PDE activity assay demonstrated higher total cAMP 
hydrolyzing activity in MCT-PH PASMCs than in control PASMCs (8.72 vs 7.66 
pmol cAMP/minute/mg protein), which were both suppressed by IBMX to a 
similar basal level (1.9 pmol cAMP/minute/mg protein) (Figure 14A). 
Interestingly, the contribution of PDE10A to the total cAMP PDE activity 
increased from 38% to 53% in MCT-PH PASMCs as opposed to control 
PASMCs (Figure 14B and 14C). In contrast, the contribution of other cAMP 
hydrolyzing PDEs (PDE1, PDE2, PDE3 and PDE4) declined from 70% to 52% 
in MCT-PH PASMCs as compared to control PASMCs (Figure 14B and 14C).  
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Figure 14: cAMP PDE activity of control and MCT PASMCs. PDE activity assay was 
performed by applying different PDE inhibitors to protein lysates of PASMCs. A) Total 
cAMP activity in control and in MCT PASMCs. The PDE activity in both was remarkably 
suppressed by a non-selective PDE inhibitor (IBMX, 200 µM) to a similar basal level (black 
bars). †P < 0.05 vs control PASMCs; ***P < 0.001 vs total activity. cAMP activity of B) 
control PASMCs and C) MCT PASMCs attributed by PDE10A or other PDEs (PDE1, PDE2, 
PDE3 and PDE4). Total cAMP PDE activity was suppressed in varying degrees by a 
PDE10A inhibitor (papaverine, 10 µM) or by a combination of inhibitors against PDE1 
(8MM-IBMX, 30 µM), PDE2 (EHNA, 30 µM), PDE3 (milrinone, 5 µM)  and PDE4 (rolipram, 
10 µM). ***P < 0.001 vs total activity. n = 3 in each group. Values are expressed as mean ± 
SEM. 
 
 
4.4.3 Cellular localization of PDE10A in rat PASMCs 
Indicated by the high abundance of PDE10A in PASMCs by 
immunohistochemistry analysis of lung sections, we further investigated the 
cellular localization of PDE10A in PASMCs. Immunofluorescence staining 
showed a predominant presence of PDE10A in the nuclei of control PASMCs 
as well as MCT PASMCs (Figure 15).  
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Figure 15: Immunocytochemical staining of PDE10A in PASMCs. Cellular localization 
of PDE10A in control PASMCs and MCT PASMCs, shown by representative 
immunofluorescence. Green (PDE10A, FITC-conjugated); Blue (nuclei, DAPI). Staining is 
shown in a 400×magnification.  
 
 
4.5 Pulmonary hypersentive PASMCs are more proliferative than control 
PASMCs 
To examine whether PASMCs from MCT-PH rats are more proliferative, we 
applied [3H]-thymidine incorporation assay on both control and MCT-PH 
PASMCs under FBS stimulation. [3H] uptake is 80% higher in MCT-PH 
PASMCs than in control PASMCs (Figure 16). Due to this pathophysiology 
relevant cell phenotype of PASMCs from MCT-PH rats as compared to control 
PASMCs, all further experiments delineating the contribution of PDE10A were 
performed in MCT PASMCs. 
 
 
 
 
 
 
 
 
 
Figure 16: Cell proliferation of control and MCT PASMCs. Thymidine uptake of control 
and MCT PASMC under 10% FBS stimulation for 24-h. [3H]-thymidine incorporation was 
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4.6 Pharmacological and genetic inhibition of PDE10A affects intracellular 
cAMP level and proliferation of PASMCs 
4.6.1 Effects of PDE10A inhibitor papaverine on cAMP accumulation and 
PASMC proliferation 
To investigate the functional role of PDE10A in MCT-PH PASMCs, we used the 
PDE10 inhibitor papaverine to block the endogenous PDE10A in PASMCs. EIA 
assay showed a basal intracellular cAMP level in MCT-PH PASMCs at 
0.53±0.02 (nmol/mg protein). Papaverine (10 µM; 25 µM) dose-dependently 
elevated intracellular cAMP to 0.87±0.20 and 1.15±0.17 (nmol/mg protein) 
respectively (Figure 17A). The proliferation of PASMCs stimulated by 10% FBS 
was reduced to 60% by 25 µM papaverine, as assessed by [3H]-thymidine 
incorporation assay (Figure 17B). 
 
A)                   B) 
                                                                                    
 
 
 
 
 
 
 
Figure 17: PDE10A inhibitor papaverine accumulates intracellular cAMP and 
attenuates PASMCs proliferation. A) Intracellular cAMP of PASMCs was remarkably 
increased after papaverine treatment. MCT PASMCs were treated with papaverine (0, 10, 
25 µM) for 24 h for cAMP EIA assay. The cAMP content of PASMC lysates is given as 
nmol/mg protein. *P < 0.05; ***P < 0.001 vs papaverine untreated. n = 4 in each group. B) 
PASMC proliferation was reduced by papaverine. After serum starvation MCT PASMCs 
were stimulated by 10% FBS alone or with papaverine (10 µM, 25 µM) for 24 h. [3H]-
thymidine incorporation was used to evaluate cell proliferation. †††P < 0.001 vs 0.1% FBS; 
*P < 0.05 vs 10% FBS. n = 4 in each group. Values are expressed as mean ± SEM. 
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4.6.2 Effects of PDE10A knockdown by si-PDE10A on cAMP accumulation 
and PASMC proliferation  
4.6.2.1 PDE10A knockdown by siRNA 
In addition to the inhibitor studies, siRNA targeting PDE10A was applied to 
knockdown the endogenous PDE10A in MCT-PH PASMCs to be more specific 
with PDE10A inhibition. PDE10A was successfully suppressed by 100 nM si-
PDE10A on the level of mRNA (25.2±0.4% of NTC) (Figure 18A), protein 
(Figure 18C) and activity (31.5±4.5% of NTC) (Figure 18D), while no changes 
accrued by 100nM scramble siRNA. In addition, to examine isoform-specific 
effects of si-PDE10A, the expression of other PDE isoforms was analyzed in 
the PASMCs treated with si-PDE10A or scramble siRNA. Results suggested 
that these effects were specific, and the PDE10A siRNA oligos had no effect on 
the expression of PDE1A, PDE3A and PDE3B isoforms (Figure 18B). 
 
A)      B) 
 
 
 
 
 
 
 
C)      D) 
 
 
 
 
 
 
 
Figure 18: Knockdown of PDE10A by specific siRNA. MCT PASMCs were transiently 
transfected with 100 nM of si-scramble or si-PDE10A for 24 h or 48 h. PASMCs treated 
with transfection reagent alone is the negative control (NTC). A) PDE10A mRNA 
expression decreased after 24 h si-PDE10A transfection, as shown by qRT-PCR. ***P < 
0.001 vs NTC. n = 3 in each group. B) PDE1A, PDE3A and PDE3B mRNA expression 
after 24 h transfection of 100 nM si-scramble (grey bars) or si-PDE10A (black bars). n = 3 
in each group. C) Representative immumoblots showed suppressed PDE10A protein 
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expression in MCT PASMCs after 48 h si-PDE10A transfection. GAPDH was taken as a 
loading control. D) Total cAMP PDE activity in MCT PASMCs was dramatically reduced by 
48 h si-PDE10A knockdown, as estimated by PDE activity assay. *P < 0.05 vs NTC. n = 4 
in each group. Values are expressed as mean ± SEM. 
 
 
4.6.2.2 Knockdown of PDE10A by siRNA accumulates intracellular cAMP 
and attenuates PASMC proliferation 
With established siRNA knockdown conditions, the cAMP level of MCT-PH 
PASMCs was examined after PDE10A suppression by siRNA. Intracellular 
cAMP was increased to 1.00±0.10 (nmol/mg protein) in si-PDE10A treated 
PASMCs, compared with 0.48±0.04 (nmol/mg protein) in untreated PASMCs or 
0.55±0.03 (nmol/mg protein) in scramble siRNA treated PASMCs (Figure 19A). 
10% FBS stimulated proliferation of MCT-PH PASMCs was remarkably 
attenuated to 60% by si-PDE10A, without any changes with scramble siRNA 
(Figure 19B).      
 
A)                                          B) 
 
 
 
 
 
 
 
Figure 19: si-PDE10A accumulates intracellular cAMP and attenuates PASMC 
proliferation. A) Intracellular cAMP was increased in MCT PASMCs after PDE10A 
knockdown by siRNA for 48 h, evaluated by EIA assay. **P < 0.01 vs NTC. n = 4 in each 
group. B) PASMC proliferation was  attenuated by 48 h PDE10A knockdown, as shown by 
[3H]-thymidine incorporation assay. †††P < 0.001 vs 0.1% FBS; *P < 0.05 vs 10% FBS. n = 
4 in each group. Values are expressed as mean ± SEM. 
 
 
4.7 Inhibiton of PDE10A modulates CREB phosphorylation  
cAMP response element binding protein (CREB) is an important downstream 
target of cAMP. We attempted to address if CREB is modulated by PDE10A 
inhibition. Immunoblots indicated CREB activation with increased phospho-
CREB (Ser133) after “loss of function” of PDE10A using papaverine (10 µM; 25 
µM) (Figure 20A) and si-PDE10A (100 nM) (Figure 20B).   
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 A)                                                               B) 
 
 
 
 
 
 
Figure 20: Activation of CREB by PDE10A inhibition. Protein from A) papaverine (24 h, 
10 µM; 25 µM) or B) si-PDE10A (48 h, 100 nM) treated MCT PASMCs was applied for 
immunoblotting against phospho-CREB (ser133) and total CREB, with GAPDH as a 
loading control. Each blot was repeated twice. 
 
 
4.8 Antiproliferative effects of PDE inhibitors on PASMCs. 
Since cAMP and cGMP are key factors in the regulation of cell cycle and 
vasculature remodeling, we tested the contribution of different PDEs to the 
proliferation of MCT-PH PASMCs by using selective PDE inhibitors. IBMX (300 
µM), as a universal PDE inhibitor, was used as a positive control and inhibited 
PASMC proliferation by 65%. PASMC proliferation was reduced similarly by ～
25% either with PDE3 inhibitor (milrinone), PDE4 inhibitor (rolipram) or PDE5 
inhibitor (sildenafil); while PDE10 inhibitor (papaverine) decreased PASMC 
proliferation by 40% (Figure 21), which is to a higher extent as compared to 
other PDE inhibitors. We concluded that among all these PDEs, PDE10 
contributes the most to proliferation of pulmonary hypertensive PASMCs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Anti-proliferative effect of isoform selective PDE inhibitors. MCT PASMCs 
underwent serum starvation and were subsequently stimulated to proliferate by 10% FBS. 
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PDE inhibitors (IBMX, 300 µM, universal PDE inhibitor; milrinone, 3 µM, PDE3 inhibitor; 
rolipram, 3 µM, PDE4 inhibitor; sildenafil, 3 µM, PDE5 inhibitor; papaverine, 25 µM, PDE10 
inhibitor) were applied respectively for 24 h. [3H]-thymidine incorporation was performed in 
the last 4 h of stimulation. †††P < 0.001 vs 0.1% FBS, ***P < 0.001 vs 10% FBS. n = 4 in 
each group. Values are expressed as mean ± SEM. 
 
 
4.9 Papaverine treatment on MCT-induced pulmonary hypertension in rats 
4.9.1 Effect of papaverine on hemodynamics 
Animal experiments with a MCT-induced PH rat model were performed to 
examine the therapeutic efficacy and anti-remodeling potential of PDE10A 
inhibition. Saline treated MCT-PH rats exhibited a significant increase in right 
ventricular systolic pressure (RVSP) on day 35 (77.2±9.74 vs 29.1±1.3 mm Hg) 
(Figure 22A), and in pulmonary vascular resistance index (PVRI) (2.90±0.24 vs 
0.90±0.13 mm Hg min/ml 100 g body weight) (Figure 22C) as compared to 
control rats. No significant changes in systemic arterial pressure (SAP) and 
systemic vascular resistance index (SVRI) occurred (Figure 22B and 22D). 
Treatment of these rats by continuous infusion of papaverine from day 21 to 
day 35 resulted in a significant reduction of RVSP (48.4±5.3 mm Hg) (Figure 
22A) and PVRI (1.73±0.28 mm Hg min/ml 100 g body weight) (Figure 22C), 
whereas SAP and SVRI did not change significantly (Figure 22B and 22D) as 
compared to saline treated animals. 
RESULTS 
- 45 - 
Con
trol
MC
T[3
5d]
/sa
line
MC
T[3
5d]
/pa
pav
erin
e
R
VS
P
(m
m
 H
g)
0
20
40
60
80
100
120  
 
*** 
† 
Con
trol
MC
T[3
5d]
/sa
line
MC
T[3
5d]
/pa
pav
erin
e
SA
P
(m
m
 H
g)
0
20
40
60
80
100
120
140
Con
trol
MC
T[3
5d]
/sa
line
MC
T[3
5d]
/pa
pav
erin
e
PV
R
I
(m
m
 H
g 
m
in
/m
l 1
00
g 
bw
)
0
1
2
3
4
 
 
*** 
† 
Con
trol
MC
T[3
5d]
/sa
line
MC
T[3
5d]
/pa
pav
erin
e
SV
R
I
(m
m
 H
g 
m
in
/m
l 1
00
g 
bw
)
0
1
2
3
4
5
A)                                                             B) 
 
 
 
 
 
 
C)                                                            D) 
 
 
 
 
 
 
 
Figure 22: Effect of papaverine on hemodynamics of MCT-PH rats. Papaverine was 
applied by continuous intravenous infusion with osmotic minipumps from day 21 to day 35. 
Control: n=9; MCT[35d]/saline: n=8; MCT[35d]/papaverine: n=8. A) Right ventricular 
systolic pressure (RVSP, mmHg), B) systemic arterial pressure (SAP, mmHg), C) 
pulmonary vascular resistance index (PVRI, mmHg min/ml 100 g body) and D) systemic 
vascular resistance index (SVRI, mmHg) are given as mean ± SEM.  ***P < 0.001 vs 
control; †P < 0.05 vs MCT[35d]. 
 
 
4.9.2 Effect of papaverine on pulmonary peripheral artery muscularization 
Morphology analysis of the degree of muscularization of the peripheral small 
pulmonary arteries (Figure 23) showed that control rat lungs consisted of a 
majority of nonmuscularized arteries (79.5±4.5%), with a small percentage of 
partially muscularized arteries (14.0±4.0%) and a smaller percentage of fully 
muscularized arteries (6.5±0.5%). In contrast, the percentage of non-
muscularized arteries decreased to 1.2±0.4%, and the percentage of partially 
and nonmuscularized arteries increased to 33.3±4.3% and 65.4±4.5% 
respectively, in saline treated MCT-PH rat lungs. Papaverine treatment 
decreased the proportion of fully muscularized arteries to 24.4±3.4%, 
accompanied by a significant increase in partially muscularized arteries to 
70.5±2.7% and in nonmuscularized pulmonary arteries to 5.0±1.2% (Figure 23). 
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A) 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Effect of papaverine on the extent of muscularization of peripheral 
pulmonary arteries. A total of 80 to 100 intra-acinar vessels were analyzed in each lung 
from each group. A) Representative double immunostaining microphotographs of the rat 
lung sections to assess the muscularization of small pulmonary arteries. Staining was 
undertaken for von Willebrand-factor (brown, endothelial cells) and αSMA (purple, smooth 
muscle cells). B) The percentage of nonmuscularized (N), partially muscularized (P), or 
fully muscularized (M) pulmonary arteries related to the total number of pulmonary arteries 
is given as mean ± SEM.  ***P < 0.001 vs control; †P < 0.05 vs MCT[35d]. 
 
 
4.10 PDE10A expression in human lungs from donors and IPAH patients 
To ascertain clinical relevance of these findings, the expression and localization 
of PDE10A was investigated in human IPAH lungs by immunohistochemistry. 
As seen in Figure 8, a strong immunoreactivity of PDE10A was observed in 
pulmonary arteries, predominantly in the medial layer, of IPAH lung tissue 
(Figure 24, e-h). In contrast, only weak expression of PDE10A was detected in 
pulmonary arteries of donor lung tissue (Figure 24, a-d). 
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Figure 24: Pulmonary vascular expression and localization of PDE10A in lung 
tissues from donor and IPAH patients. Representative PDE10A immunostaining 
microphotographs of the human lung sections from donors (a-d) and IPAH patients (e-h). 
Scale bar: 20 µm. 
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5 DISCUSSION 
It is widely accepted that phosphodiesterases are key factors regulating the 
pulmonary vascular tone89-92 by mediating NO/cGMP pathway in pulmonary 
vasculature and PDE inhibitors are proved to be potent pulmonary artery 
relaxants in PAH80, 93-95. More recently, it was demonstrated that other than 
involvement in vascular tone, PDEs play an important role in modulating 
various signaling pathways in pulmonary vascular remodeling, via the tight 
control of the second messages - cAMP and cGMP. PDE1, PDE3, PDE4 and 
PDE5 have been reported to be increased in the vasculature of lung and 
inhibitors to those PDE subfamilies could suppress pulmonary vascular 
remodeling78, 80-83, 96, 97. However in addition to those well explored isoforms, 
there are some newly identified PDE isoforms (PDE7-11) in the PDE family. 
This brings up an important issue whether these PDEs are also involved in the 
pathogenesis of PAH. So it is of interest to determine the expression profile of 
those newly identified PDEs and to uncover which pathophysiological roles they 
may play in the development of PAH.   
 
5.1 PDE7-11 in PAH 
The present data demonstrate that multiple newly identified PDEs are 
expressed and altered (PDE7A, PDE7B and PDE10A) in the lungs of MCT-
induced pulmonary hypertensive rats. The mRNA expression analysis of PDE7-
11 in the lungs and in PASMCs demonstrated interesting tissue and cell 
specific patterns along with modulation of PDEs in healthy and hypertensive 
lungs. PDE10 isoform is mostly reported in brain diseases, based on the 
concept that PDE10A is not widely expressed outside of the central nervous 
system. However, we observed increased expression of PDE10A in MCT-PH 
lungs and MCT PASMCs as compared to controls. PDE7 is mostly involved in 
the immune system, such as T cell activation98. An upregulation of PDE7A and 
PDE7B was observed in MCT-PH rat lungs, whereas only PDE7A was 
upregulated in MCT-PH PASMCs as compared to control PASMCs, suggesting 
a distinct cellular localization of these two PDE7 isoforms. In accordance, 
PDE7A isoform was detected by RT-PCR in vascular SMCs other than in T 
lymphocytes, monocytes, neutrophils, airway SMCs, lung fibroblasts, epithelial 
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cells, and cardiac myocytes99-102 and has been implicated in the pathogenesis 
of chronic obstructive pulmonary disease and asthma100, 103. However, protein 
expression analysis of PDE7A in lungs and in PASMCs revealed a weak 
expression of PDE7A in pulmonary vasculature and with no significant changes 
in MCT PASMCs as compared to control PASMCs (data not shown). This 
suggests discordance between transcriptional and translational regulation of 
PDE7A in MCT-induced pulmonary vascular remodeling and needs further 
investigations. 
 
5.2 PDE10A in PAH 
An immunohistochemical study of PDE10A localization in the major mammalian 
tissues demonstrated the lack of PDE10A immunoreactivity in the peripheral 
organs (liver, kidney, lung, spleen, or heart) of any species. Different from their 
finding, in our studies we found the presence of PDE10A in lung vasculature. 
Moreover, PDE10A expression is prominently induced in the structurally 
remodeled pulmonary arterial muscular layer. In accordance, PDE10A mRNA 
and protein expression are increased in PASMCs isolated from MCT-PH rats 
as compared to control rats. Moreover, PDE10A is one of the major cAMP 
hydrolyzing PDEs and contributes more to the total cAMP PDE activity in MCT-
PH PASMCs compared with control PASMCs. Taken together, all these data 
suggest a likely contribution of PDE10A in the pathogenesis of PAH. 
 
The tissue distribution and cellular localization of PDEs are important clues to 
understand their pathophysiological functions and apply potential therapeutic 
strategies. PDE expression in a particular organ or cell type could suggest 
potential effects of a corresponding PDE inhibitor in vivo. For example, high 
levels of PDE5 expression in corpus cavernosum and lung are consistent with 
the therapeutic benefits in treating erectile dysfunction and pulmonary 
hypertension, respectively104, 105. PDE10A was identified only 10 years ago and 
demands a better understanding of its functions. Unique distribution of PDE10A 
in the brain and its enrichment in the striatum, made PDE10A as a potential 
therapeutic target for the treatment of neurological and psychiatric disorders106-
109. Recently nuclear PDE10A staining was noted in some endocrine organ and 
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PDE10A-selective inhibitors have also been claimed to be useful for the 
treatment of diabetes and obesity110.  
 
Although well characterized in brain, PDE10A is sparsely addressed in adult 
lung tissue69. The stronger expression in pulmonary arteries and in isolated 
PASMCs from the MCT-PH rat in our studies suggests that PDE10A may 
contribute to the proliferative phenotype of PASMCs. Although the specific 
functional role of PDE10A in lung tissue needs to be further characterized, this 
study also suggests a reactivation of PDE10A signaling in abnormal 
proliferative lung disease tissues, such as the tissues observed in pathological 
vascular remodeling. Moreover, we also found that PDE10A immunoreactivity 
was strongly increased in pulmonary arteries of IPAH patient lung sections as 
compared to the donors, indicating clinical relevance of the findings obtained 
from the MCT model. 
 
5.3 Influence of PDE10A on PASMC proliferation   
Vascular remodeling, which includes proliferation and hypertrophy of smooth 
muscle cells, is a characteristic feature of PAH8, 111. Recent studies have 
reported that targeting abnormal media proliferation blocks the development of 
PAH and attenuates pulmonary arterial remodeling in rodents and humans8, 58, 
59, 112. In the MCT-induced PH model, we found that PASMCs from MCT rats 
are much more proliferative than PASMCs from control rats, a result consistent 
with the reports demonstrating that PASMCs from pulmonary hypertensive 
vessels possess larger mitogenic potent85, 113. In our studies, a selective 
PDE10A inhibitor as well as selective PDE10A siRNA suppressed proliferation 
of PASMCs. More interestingly, among the major cAMP-hydrolyzing PDE 
inhibitors, PDE10 inhibitor papaverine was the most potential one to reduce 
PASMC proliferation. In this aspect, PDE10 selective inhibitors may thus act as 
more efficient anti-proliferative drugs compared with other PDE specific 
inhibitors, implying that PDE10A could be a useful therapeutic target for PAH 
and for other disorders characterized by increased PASMC proliferation.  
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5.4 Signaling pathway related to anti-prolifeative effect of PDE10 inhibiton   
Regarding to the critical role of cyclic nucleotide on cell proliferation, both 
cGMP and cAMP are believed to inhibit SMC proliferation in vitro and in vivo114, 
115. By applying the 8-Br-cAMP, a cAMP analogue resistant to PDE-mediated 
hydrolysis, cell cycle traverse was suppressed116. Also the unspecific PDE 
inhibitor IBMX - by inhibiting cAMP hydrolysis - can block the PASMCs 
proliferation stimulated by growth factors97. Moreover PDE3 and PDE4, as 
cAMP- PDEs, have been shown to play an essential role in cAMP catabolism in 
experimental PAH models and combined PDE 3/4 inhibitors increase cAMP 
levels and reverse pulmonary vascular remodeling82. Although PDE10A is a 
dual-substrate PDE, it is reported that the enzyme activity is stimulated by 
cAMP being bind to the GAF domains of PDE10A73, 74. Taken together, we 
speculate that PDE10A may mainly control cAMP level under the 
pathophysiological conditions, although we can not exclude the involvement of 
cGMP117. 
 
These anti-proliferative effects are largely due to an increase in intracellular 
cAMP level that may subsequently stimulate the activity of protein kinase A 
(PKA)118, 119. cAMP, produced by activation of G protein-coupled receptors 
(GPCRs) and activation of adenylate cyclases, binds to the regulatory subunits 
of PKA to release the catalytic subunits. In the cytoplasm, PKA catalytic 
subunits phosphorylate downstream targets; while in the nucleus, PKA catalytic 
subunits phosphorylate cAMP response element-binding protein (CREB), 
resulting in activation of DNA transcription of cAMP-responsive element-
containing genes. Deactivation of cAMP/PKA pathway is accomplished through 
degradation of cAMP to 5’AMP by cAMP-PDEs120, 121 (Figure 25). In line with 
this notion, several studies from our group and others have reported that 
compounds which activate adenylate cyclase or inhibit PDE counteract several 
pathways involved in SMC proliferation78, 83, 122. For example, cAMP in vascular 
SMCs was shown to decrease the expression of cyclin D1 and cdk2 as well as 
extracellular signal-regulated kinase (ERK) activation, and to increase the 
expression of the anti-proliferative molecules such as p53 and p21114, 123-125. In 
addition, there is now substantial evidence that cAMP/PKA signaling acts as a 
molecular gate to block cell cycle progression, largely via occupancy of the 
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cAMP response elements (CRE) in the promoter region of the cyclin A gene, 
along with an increase in the level and phosphorylation status of the CREB 
transcription factor126. But intracellular mechanisms leading to CREB 
phosphorylation are diverse, as well as the cellular responses after CREB 
phosphorylation are multiple127. From the research of PDE10A in brain, it was 
demonstrated that papaverine increases cAMP level and CREB 
phosphorylation by inhibiting PDE10A128. In accordance, we found that the ratio 
of phosphorylated CREB to total CREB was significantly increased in PASMCs 
after PDE10A inhibition by papaverine and PDE10A-selective siRNA. This may 
have important consequences for PAH in vivo, since CREB content has been 
shown to be diminished in SMCs in remodeled pulmonary arteries with PAH129.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Diagram of the cAMP/PKA signaling in normal cells. (Modified from Bossis, 
I., 2004) 
 
5.5 Therapeutic effects of a PDE10 inhibitor on MCT-induced PH 
A couple of experimental or preclinical experiments showed PDE inhibitors 
exhibit therapeutic improvement not only via vascular relaxation, more 
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important, via reversing pulmonary vascular remodeling78-81. Cyclic nucleotide-
mediated cellular responses are governed not only by alterations in PDE 
expression but also by the activity of specific types of PDE isoforms. Studies on 
hypoxic PAH rat suggests that decrease in intracellular cyclic nucleotide levels 
in pulmonary arteries from pulmonary hypertensive rats is associated with 
increased PDE activity77, 113. Recently, Murray et al., demonstrated that the total 
cAMP-PDE and cGMP-PDE activity is increased in PAH PASMCs as compared 
to control PASMCs97. They investigated only the contribution of PDE1-5 to the 
total cAMP PDE activity and concluded that the increased the cAMP activity is 
mainly from PDE3 isoform. In agreement with these findings, an increase in the 
total cAMP-PDE activity was observed in a well-established experimental 
model of PH in our study. Notably, the relative contribution of PDE10A to total 
cAMP-PDE activity was found to be increased in MCT-PH PASMCs as 
compared to control PASMCs, indicating that PDE10A inhibition was more 
effective in increasing cAMP generation and inhibiting hyperproliferation of 
PASMCs from MCT-PH rats. This suggests that PDE inhibitors that raise cAMP 
in general, as well as PDE10A-selective inhibitors, offer a new target for 
therapeutic intervention in pulmonary hypertension. In line, treatment of MCT-
PH rats with the PDE10A inhibitor papaverine for 14 days markedly improved 
pulmonary hemodynamics. Right ventricular systolic pressure was significantly 
lowered as well as total pulmonary vascular resistance index with papaverine 
treatment, with no systemic effects. The structural changes of the lung 
vasculature such as high percentage of fully muscularized peripheral 
pulmonary arteries were significantly decreased with papaverine treatment. 
However, since papaverine is used as a potent vasodilator in the systemic and 
cerebral vasculature, we couldn’t rule out the possibility that papaverine may 
exert vasodilatory effect on pulmonary vessels130. Papaverine-induced 
vasorelaxation is believed to be related to reduced calcium influx following PAK 
activation after cAMP increase131, 132. Of note, although papaverine offers a 
good opportunity for the preclinical studies as a relatively selective PDE10 
inhibitor, still new PDE10 inhibitors with higher selectivity and potency are 
required to further explore the therapeutic aspects. 
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5.6 Limitations 
A limitation of this study is that the in vivo experiments were carried out in MCT-
induced PH rat model133-135. Monocrotaline is a toxic pyrrolizidine alkaloid from 
the plant Crotalaria spectablis. After a sinle injection of subcutaneous injection 
of MCT in rats, MCT is transformed in the liver to the active compound - MCT 
pyrrole, which bio-functionally leads to vascular injury136. Although it is the most 
commonly employed PH animal model to study the pathophysiological and 
possible therapeutic approaches, the exact mechanism through which MCT 
causes PH is not known completely yet. Most of the investigators believe that 
MCT causes endothelial injury, which eventually leads to medial hypertrophy 
and vasoconstriction in the pulmonary arterioles with no formation of intimal 
lesions in the peripheral pulmonary arteries136, 137. In contrast, the characteristic 
pathological changes in human pulmonary arterial hypertension include medial 
hypertrophy, intimal proliferation, in situ thrombosis, and plexiform lesions138. 
Thus, the results obtained from the MCT model may not be predictive of 
response to therapy in humans and needs to be evaluated in other alternative 
animal models of PAH. However, the increased immunoreactivity of PDE10A in 
remodelled pulmonary vasculature of IPAH patients show clinical relevance and 
promise to proceed further.  
 
5.7 Conclusion and perspectives 
In the present study, PDE10A expression and activity are shown to be 
increased in lung tissue and PASMCs of experimental PH. Loss-of-function 
studies using the PDE10A inhibitor papaverine and PDE10A-targeted siRNA 
showed increased cAMP generation and CREB phosphorylation, and reduced 
proliferation of PASMCs from MCT-PH rats. However the mechanism 
underlying those effects has not been clearly demonstrated. The common 
cAMP/PKA signaling is shown in the schematic overview of Figure 26. Agonists 
such as prostacyclin bind to receptors and activate G proteins, which in turn 
activate adenylyl cyclase to release cAMP. After binding of cAMP to the 
homodimer of regulatory subunits (RIα), catalytic subunits (PKAC) are released. 
Cytoplasma PKAC phosphorylates multiple cytoplasmatic targets. PKAC can 
also been translocated to nucleus and phosphorylates CREB, resulting in 
activation of DNA transcription of CRE-containing gene. We found that PDE10A 
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is majorly presented in nucleus, so it would be important to investigate if this 
specific compartmentalization of PDE10A regulates degradation of nuclear 
cAMP and cGMP, which may mediate relative cellular responses contributing to 
vascular remodeling.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Scheme of cyclic nucleotide signaling system regulated by PDE10 in 
PASMCs. 
 
The cellular response demonstrated that PDE10A plays a major role in the 
hyperproliferation of PASMCs. Furthermore, intravenous infusion of papaverine 
significantly improved pulmonary hemodynamics and significantly reversed 
structural changes underlying MCT-induced PH in rats. To the best of our 
knowledge this is the first study indicating a central role of PDE10A in 
progressive pulmonary vascular remodelling. Based on our findings, we 
speculate that PDE10 inhibition present a novel therapeutic approach to the 
treatment of PAH.  
 
Taken together, we have shown in this study the role of PDE10A in pulmonary 
vascular remodeling in a MCT-PH rat model and this offers another potent 
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theorapeutic option for PAH. It is of interest to examine on other models such 
as hypoxia PH model, as well to evaluate that if PDE10A is importantly involved 
in the pathogenesis of PAH patients. 
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